Introduction: Bevacizumab, an anti‐VEGF antibody, inhibits angiogenesis and modulates the tumor microenvironment. Because systemic inflammation is linked to VEGF activation and immune modulation, it may affect bevacizumab efficacy. However, this relationship remains unclear. We therefore evaluated whether systemic inflammation, assessed via the serum C‐reactive protein (CRP) level, modifies survival benefit when adding bevacizumab to chemoimmunotherapy in advanced non‐squamous non‐small cell lung cancer (NSCLC). Methods: We retrospectively analyzed patients with advanced non‐squamous NSCLC from 13 Japanese institutions receiving first‐line atezolizumab plus chemotherapy with or without bevacizumab between December 2018 and December 2022. The primary endpoint was overall survival (OS). The interaction between CRP level (< 1 mg/dL vs. ≥ 1 mg/dL) and bevacizumab treatment was evaluated, and sensitivity analyses were performed to confirm the robustness of our findings. Results: Among 193 eligible patients, 109 (56.5%) received bevacizumab. With a median follow‐up of 44.2 months, the median OS was 24.5 months in patients with low CRP and 17.3 months in those with high CRP (log‐rank test for trend, p = 0.04). Bevacizumab significantly improved OS in patients with high CRP (hazard ratio [HR] 0.63; 95% confidence interval, 0.40–0.99; p = 0.04), but not in those with low CRP (HR 1.22; p = 0.50). The interaction between CRP level and bevacizumab treatment was significant ( p = 0.033). Sensitivity analyses supported these results. Conclusions: Systemic inflammation, as assessed by CRP level, may modify the efficacy of bevacizumab in advanced non‐squamous NSCLC. These hypothesis‐generating findings warrant prospective validation to clarify the role of CRP in treatment stratification.
Background/Aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear. Patients and Methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70). Conclusion: In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.
8 June 2025 in International Cancer Conference Journal